MoonLake Immunotherapeutics
MLTX15.510USD
+0.740+5.01%
終値 02/06, 16:00（ET）15分遅れの株価
988.06M時価総額
損失額直近12ヶ月PER
詳細情報 MoonLake Immunotherapeutics 企業名
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeuticsの企業情報
企業コードMLTX
会社名MoonLake Immunotherapeutics
上場日Oct 20, 2020
最高経営責任者「CEO」Santos Da Silva (Jorge)
従業員数100
証券種類Ordinary Share
決算期末Oct 20
本社所在地Dorfstrasse 29
都市ZUG
証券取引所NASDAQ OMX - NASDAQ BASIC
国Switzerland
郵便番号6300
電話番号41415108022
ウェブサイトhttps://moonlaketx.com/
企業コードMLTX
上場日Oct 20, 2020
最高経営責任者「CEO」Santos Da Silva (Jorge)
MoonLake Immunotherapeuticsの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.96M
-167519.00%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.28M
+354296.00%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.96M
-167519.00%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.28M
+354296.00%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sat, Feb 7
更新時刻: Sat, Feb 7
株主統計
種類
株主統計
株主統計
比率
BVF Partners L.P.
27.88%
Deep Track Capital LP
6.51%
Santos da Silva (Jorge)
4.34%
Reich (Kristian)
4.18%
Avoro Capital Advisors LLC
2.82%
他の
54.27%
株主統計
株主統計
比率
BVF Partners L.P.
27.88%
Deep Track Capital LP
6.51%
Santos da Silva (Jorge)
4.34%
Reich (Kristian)
4.18%
Avoro Capital Advisors LLC
2.82%
他の
54.27%
種類
株主統計
比率
Hedge Fund
47.83%
Individual Investor
10.56%
Investment Advisor
6.71%
Investment Advisor/Hedge Fund
5.77%
Research Firm
1.10%
Venture Capital
0.49%
Sovereign Wealth Fund
0.33%
Bank and Trust
0.11%
Pension Fund
0.04%
他の
27.06%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
347
43.70M
61.69%
-21.61M
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BVF Partners L.P.
19.75M
27.88%
--
--
Nov 06, 2025
Deep Track Capital LP
4.61M
6.51%
+4.61M
--
Nov 05, 2025
Santos da Silva (Jorge)
3.07M
4.34%
-3.68K
-0.12%
Dec 19, 2025
Reich (Kristian)
2.96M
4.18%
-167.52K
-5.35%
Dec 19, 2025
Avoro Capital Advisors LLC
2.00M
2.82%
-2.15M
-51.81%
Sep 30, 2025
Cormorant Asset Management, LP
1.99M
2.81%
-6.50M
-76.52%
Sep 30, 2025
Balyasny Asset Management LP
1.70M
2.4%
+1.28M
+301.55%
Sep 30, 2025
Adage Capital Management, L.P.
1.50M
2.12%
+1.50M
--
Sep 30, 2025
Bodenstedt (Matthias)
922.01K
1.3%
+294.47K
+46.93%
Dec 19, 2025
Schonfeld Strategic Advisors LLC
965.40K
1.36%
+965.40K
--
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.22%
Virtus LifeSci Biotech Clinical Trials ETF
0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.02%
Strive Small-Cap ETF
0.02%
Nuveen ESG Small-Cap ETF
0.02%
iShares Morningstar Small-Cap ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
詳細を見る
ALPS Medical Breakthroughs ETF
比率0.27%
Global X Guru Index ETF
比率0.22%
Virtus LifeSci Biotech Clinical Trials ETF
比率0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
比率0.02%
Strive Small-Cap ETF
比率0.02%
Nuveen ESG Small-Cap ETF
比率0.02%
iShares Morningstar Small-Cap ETF
比率0.01%
John Hancock Multifactor Small Cap ETF
比率0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
比率0.01%
Fidelity Nasdaq Composite Index ETF
比率0.01%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
